Positive results have been obtained from the Phase II clinical trial of scyllo-inositol (ELND005) for the treatment of young adults with Down Syndrome Clinical Trials which was carried out at Massachusetts General Hospital in the United States.

Scyllo-inositol was initially being developed as an Alzheimer's disease treatment option.

According to the findings, 22 of the total 23 patients between the ages of 18 and 45 have successfully completed the study without significantly deviating from the protocol.
Scyllo-inositol 250 mg daily or twice daily was compared to a placebo in the four-week study.

According to reports, Down syndrome, which is characterized by varying degrees of intellectual disability and a high risk of Alzheimer's dementia, is caused by the presence of an additional copy of chromosome 21.

"The results indicated that 22 of the 23 patients aged 18 to 45 have completed the trial without significant deviations from the protocol," the researchers wrote.
One of the genes on chromosome 21 is responsible for the metabolism of myo-inositol, which may contribute to the severity of symptoms, and another gene on chromosome 21 is thought to be responsible for the cognitive difficulties associated with Down syndrome.

By regulating myo-inositol-dependent brain signaling and lowering amyloid levels, scyllo-inositol is thought to have the potential to enhance Down syndrome-related cognition.

To know about the assumptions considered for the study, Download for Free Sample Report

Brian Skotko, co-director of the Down Syndrome Program at Massachusetts General Hospital and the trial's site principal investigator, stated: Members of the Down syndrome community have made it abundantly clear through this study that they are eager to participate in clinical trials, particularly those that hold promise for Alzheimer's disease treatment.
The duration of the trial is thought to be insufficient to evaluate the changes in cognitive or behavioral behavior, and it did not reveal any significant adverse events or changes in physical findings like vital signs or laboratory tests.

Transition Therapeutics is developing scyllo-inositol, and Elan Pharmaceuticals supported the trial.